Squarepoint Ops LLC Lowers Position in Repligen Co. (NASDAQ:RGEN)

Squarepoint Ops LLC reduced its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 85.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 14,291 shares of the biotechnology company's stock after selling 81,814 shares during the period. Squarepoint Ops LLC's holdings in Repligen were worth $2,057,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Signaturefd LLC lifted its position in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new stake in Repligen during the fourth quarter worth $29,000. Raiffeisen Bank International AG bought a new stake in shares of Repligen during the 4th quarter worth $29,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Repligen in the 4th quarter valued at approximately $40,000. Finally, Global Retirement Partners LLC boosted its position in Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after buying an additional 129 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded down $4.66 during midday trading on Friday, reaching $117.66. The company had a trading volume of 1,145,832 shares, compared to its average volume of 743,710. The stock has a market cap of $6.61 billion, a P/E ratio of -230.71, a P/E/G ratio of 4.54 and a beta of 1.21. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52-week low of $102.97 and a 52-week high of $182.52. The company's 50 day moving average price is $128.09 and its 200 day moving average price is $143.69.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business's revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 earnings per share. As a group, sell-side analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Evercore ISI assumed coverage on Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target on the stock. Royal Bank of Canada cut their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. JPMorgan Chase & Co. reduced their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. HC Wainwright reiterated a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Monday, May 5th. Finally, Canaccord Genuity Group decreased their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.

Insider Activity at Repligen

In related news, Director Margaret Pax bought 250 shares of the business's stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.